Shionogi, JP3347200002

Shionogi stock gets a USD 2.0 billion rare disease deal

Published on 10/07/2026 at 04:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Shionogi stock reported JPY 163.31 billion in Q1 fiscal 2027 revenue on June 30, 2026. The October 5, 2026 deal adds AQNEURSA to its rare disease portfolio.

Shionogi, JP3347200002, Illustration mit AI erstellt.

Shionogi stock (ISIN JP3347200002) was last at JPY 2,760.50 on the Tokyo Stock Exchange on October 7, 2026 at 11:30 a.m. JST, down 0.09 percent from the prior close. The pharmaceutical group is pursuing a USD 2.0 billion acquisition to expand its rare disease business, according to Shionogi on October 5, 2026.

USD 2.0 billion rare disease deal

Shionogi agreed to acquire all outstanding shares of IntraBio for an upfront cash consideration of USD 2.0 billion. The transaction would add AQNEURSA, an approved treatment for neurological manifestations of Niemann-Pick disease type C and Ataxia-Telangiectasia, to Shionogi's portfolio.

The agreement is scheduled for execution between November 2026 and December 2026, subject to customary closing conditions and regulatory clearances. Shionogi said the transaction's impact on consolidated results for the fiscal year ending March 2027 remains under review, according to Shionogi.

Q1 revenue reached JPY 163.31 billion

Shionogi's Q1 fiscal 2027 revenue was JPY 163.31 billion for the period ended June 30, 2026, while earnings reached JPY 97.7 billion. Yahoo Finance identifies the figures as Q1 FY27 revenue and earnings, giving investors a current operating reference alongside the acquisition plan.

The Q1 figures put the deal in a different perspective: the USD 2.0 billion upfront payment is being made against a company whose strategic value rests on AQNEURSA, additional rare disease capabilities and a pipeline that includes Pompe disease, Fragile X syndrome and Jordan's syndrome programs.

Analyst target stands above the share price

The analyst consensus for Shionogi is Buy, based on 12 analysts, with five Buy ratings and seven Holds. According to Investing.com, the average 12-month target is JPY 3,358.3, with a high of JPY 4,000 and a low of JPY 2,900.

The average target lies 21.7 percent above the JPY 2,760.50 price. Jefferies separately maintained a Buy rating and a JPY 3,800 target in a September 2026 note, as reported by Dow Jones Newswires.

Stock remains below its yearly high

At JPY 2,760.50 on October 7, 2026, the stock was 26.5 percent below its 52-week high of JPY 3,758.00 and above its low of JPY 2,153.50. The market capitalization was JPY 2.3 trillion and trading volume was 1,200,900 shares on the same session.